Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$1.69
+1.20%
Mkt Cap $137.04M
Analyst Ratings
No recent rating data.
Price Target (3 analysts)
$4.00
Range $4.00 – $4.00
Implied Upside
+137.4%
Consensus $4.00 vs current $1.69
NASDAQ·Healthcare·Biotechnology
$1.69
+1.20%
Mkt Cap $137.04M
No recent rating data.
Price Target (3 analysts)
$4.00
Range $4.00 – $4.00
+137.4%
Consensus $4.00 vs current $1.69